BACKGROUND: Deleted in liver cancer-1 (DLC-1) is a tumour suppressor gene that is inactive in liver carcinogenesis. It encodes a rho-guanosine triphosphatase-activating protein (rho-GAP) and maps to one of the deleted regions (8p21.3-22). Little is known, however, about the methylation status of the DLC-1 promoter in myeloma cells. AIM: To identify whether methylation of DLC-1 was associated in pathogenesis of multiple myeloma. METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect DLC-1 transcripts in RPMI 8226, U266, OPM-2 and XG-2 cell lines. The methylation status was determined by methylation-specific PCR followed by bisulphite DNA sequencing in these four cell lines and in the bone marrow of 14 patients with multiple myeloma and 4 normal patients. DLC-1 mRNA expression in cells with or without treatment with 5-aza-deoxycytidine (5-aza-CdR) or trichostatin A (TSA) was investigated by real-time RT-PCR. RESULTS: RPMI 8226 and U266 showed complete methylation and XG-2 showed partial methylation. DLC-1 was expressed only in OPM-2 cell lines that showed no methylation. DLC-1 methylation was shown in 11 of 14 (78%) patients with multiple myeloma and none of the normal controls. The exposure of cell lines to 5-aza-CdR or TSA resulted in the up regulation of DLC-1 gene expression. CONCLUSIONS: DLC-1 methylation is often present in multiple myeloma and has a key role in DLC-1 silencing.
BACKGROUND:Deleted in liver cancer-1 (DLC-1) is a tumour suppressor gene that is inactive in liver carcinogenesis. It encodes a rho-guanosine triphosphatase-activating protein (rho-GAP) and maps to one of the deleted regions (8p21.3-22). Little is known, however, about the methylation status of the DLC-1 promoter in myeloma cells. AIM: To identify whether methylation of DLC-1 was associated in pathogenesis of multiple myeloma. METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect DLC-1 transcripts in RPMI 8226, U266, OPM-2 and XG-2 cell lines. The methylation status was determined by methylation-specific PCR followed by bisulphite DNA sequencing in these four cell lines and in the bone marrow of 14 patients with multiple myeloma and 4 normal patients. DLC-1 mRNA expression in cells with or without treatment with 5-aza-deoxycytidine (5-aza-CdR) or trichostatin A (TSA) was investigated by real-time RT-PCR. RESULTS:RPMI 8226 and U266 showed complete methylation and XG-2 showed partial methylation. DLC-1 was expressed only in OPM-2 cell lines that showed no methylation. DLC-1 methylation was shown in 11 of 14 (78%) patients with multiple myeloma and none of the normal controls. The exposure of cell lines to 5-aza-CdR or TSA resulted in the up regulation of DLC-1 gene expression. CONCLUSIONS:DLC-1 methylation is often present in multiple myeloma and has a key role in DLC-1 silencing.
Authors: P J Wilson; E McGlinn; A Marsh; T Evans; J Arnold; K Wright; K Biden; J Young; B Wainwright; C Wicking; G Chenevix-Trench Journal: Hum Mutat Date: 2000 Impact factor: 4.878
Authors: Ya-Wei Qiang; Katie Walsh; Lei Yao; Noemi Kedei; Peter M Blumberg; Jeffrey S Rubin; John Shaughnessy; Stuart Rudikoff Journal: Blood Date: 2005-05-10 Impact factor: 22.113
Authors: Bao-Zhu Yuan; Xiaoling Zhou; Marian E Durkin; Drazen B Zimonjic; Katrin Gumundsdottir; Jorunn E Eyfjord; Snorri S Thorgeirsson; Nicholas C Popescu Journal: Oncogene Date: 2003-01-23 Impact factor: 9.867
Authors: Xiaolan Qian; Guorong Li; Holly K Asmussen; Laura Asnaghi; William C Vass; Richard Braverman; Kenneth M Yamada; Nicholas C Popescu; Alex G Papageorge; Douglas R Lowy Journal: Proc Natl Acad Sci U S A Date: 2007-05-15 Impact factor: 11.205
Authors: Tai Young Kim; In Sook Kim; Hyun Soon Jong; Jung Weon Lee; Tae You Kim; Mira Jung; Yung Jue Bang Journal: Exp Mol Med Date: 2008-12-31 Impact factor: 8.718
Authors: Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu Journal: J Cell Mol Med Date: 2007 Sep-Oct Impact factor: 5.310